Healthcare entity
Keytruda is the most frequent co-covered peer, appearing in 2 of the 3 tracked stories. Across a 151-day span, the pace is roughly 0.1 stories per week. The busiest single day carried 2. Coverage clusters in acquisition, which accounts for 2 of those 3, with the remainder spread across 1 other category.
Last mentioned: 1d ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Keytruda is the most frequent co-covered peer, appearing in 2 of the 3 tracked stories. Across a 151-day span, the pace is roughly 0.1 stories per week. The busiest single day carried 2. Coverage clusters in acquisition, which accounts for 2 of those 3, with the remainder spread across 1 other category. They are less corroborated than the beat average, carrying 2 original sources each against 3.7 for the same window. Their average consequence score of 7.3 runs above the beat's 6 for that window. We currently track 3 Healthcare stories that mention Terns Pharmaceuticals, published between March 25, 2026 and August 22, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 556 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Terns Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Keytruda Patent Expiration
The primary patent for Merck's blockbuster drug Keytruda expires, opening the door for biosimilars.
Pipeline Integration
Merck integrates Terns' small-molecule oncology candidates into its global R&D infrastructure.
Expected Closing
Anticipated completion of the acquisition following regulatory and shareholder approvals.
Argus raises Merck price target
Argus lifts its Merck target from $130 to $145 with a Buy rating, citing pipeline depth and clinical progress.
Merck discloses Evaxion stake
Merck reports holding 1,214,126 shares of Evaxion A/S in a regulatory filing.
Expected Closing
Anticipated completion of the acquisition following regulatory reviews.
Acquisition Announced
Merck and Terns Pharmaceuticals announce a definitive $6.7 billion merger agreement.
Merck exercises EVX-B3 option
Merck decides to in-license Evaxion's discovery-stage AI-derived vaccine candidate EVX-B3 against an undisclosed bacterial pathogen.
Clinical Progress
Terns Pharmaceuticals advances TERN-701 through early-stage clinical trials for CML.
Merck's disclosure of a 1.21 million-share stake in Evaxion A/S signals growing pharma confidence in AI-discovered vaccine candidates. For health systems, the partnership could accelerate a new class of antigen-targeted vaccines for bacterial pathogens.
Merck has reached a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a promising Phase 2 leukemia treatment. The cash deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its blockbuster drug Keytruda.
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, a strategic move designed to diversify its oncology portfolio. The acquisition comes as Merck prepares for the impending patent expiration of its top-selling cancer immunotherapy, Keytruda, later this decade.
Source: abcnews.com · clickorlando.com
Terns Pharmaceuticals is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
